Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.61 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | DHODH | Q02127 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408811 | 0.92 | MEN1 (0.64) | SERPINE1MEN1KMT2ADHODHNPC1 | |
| SCHEMBL8027764 | 0.90 | MEN1 (0.67) | SERPINE1MEN1KMT2ADHODHNPC1 | |
| SCHEMBL30466712 | 0.88 | MEN1 (0.72) | SERPINE1MEN1KMT2ADHODHNPC1 | |
| SCHEMBL2025586 | 0.88 | MEN1 (0.72) | SERPINE1MEN1KMT2ADHODHNPC1 | |
| SCHEMBL6339040 | 0.88 | ELANE (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2292518 | 0.87 | SERPINE1 (0.71) | SERPINE1MEN1KMT2ADHODHNPC1 | |
| SCHEMBL2276745 | 0.85 | SERPINE1 (0.65) | SERPINE1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2330281 | 0.85 | MEN1 (0.69) | SERPINE1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2274898 | 0.83 | SERPINE1 (0.60) | SERPINE1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6337620 | 0.83 | PLK1 (0.60) | HCAR2SERPINE1MEN1KMT2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | HCAR2 274/4885SERPINE1 4734/4885MEN1 3155/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | HCAR2 387/4885SERPINE1 4640/4885MEN1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.